← Back to Search

Unknown

Lucid-21-302 for Healthy Subjects

Phase 1

Waitlist Available

Led By Isabella Szeto, MD

Research Sponsored by FSD Pharma, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-dose to 48 hours post-dose

Awards & highlights

Study Summary

This trial tests the safety, side effects and how a drug is absorbed and used in the body in healthy adults. It also looks at how food affects the drug.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-dose to 48 hours post-dose

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-dose to 48 hours post-dose

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose to 48 hours post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

AUC from time zero to the last non-zero concentration after single dose

AUC0-inf after single dose

CL/F after single dose

+14 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Lucid-21-302Experimental Treatment1 Intervention

Single-ascending dose cohorts

Group II: PlaceboPlacebo Group1 Intervention

Single-ascending dose cohorts

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lucid-21-302

2023

Completed Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

FSD Pharma, Inc.Lead Sponsor

2 Previous Clinical Trials

55 Total Patients Enrolled

Lucid Psycheceuticals Inc. (sub of FSD Pharma, Inc.)UNKNOWN

Isabella Szeto, MDPrincipal InvestigatorBiopharma Services Incorporated

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are elderly individuals eligible to participate in this scientific endeavor?

"As outlined in the trial's inclusion criteria, eligible participants must be of legal age (18+) and no older than 60 years old."

Answered by AI

Is it feasible for me to sign up as a participant in this trial?

"To be eligible for this clinical research, candidates must have strong health histories and lie between the ages of 18-60. This trial is currently recruiting 56 participants in total."

Answered by AI

Has the FDA sanctioned Lucid-21-302 for medical purposes?

"The safety rating of Lucid-21-302 is estimated to be a 1, as it has only undergone Phase 1 trials with limited evidence regarding efficacy and safety."

Answered by AI

Are there any vacancies to join the research study?

"The latest data on clinicaltrials.gov indicates that this trial, initially posted in March of 2023 is currently recruiting participants. It was last edited on April 6th 2023."

Answered by AI

How many participants are being accepted for inclusion in this clinical trial?

"Affirmative. Clinicaltrials.gov's records indicate that this clinical trial, which was published on March 22nd 2023, is actively looking for participants. In total, 56 individuals must be sourced from 1 medical centre in order to reach the study goal."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers

2023. "Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05821387.